Format

Send to:

Choose Destination
See comment in PubMed Commons below
Future Med Chem. 2012 Sep;4(13):1701-13. doi: 10.4155/fmc.12.110.

Current understanding of LRRK2 in Parkinson's disease: biochemical and structural features and inhibitor design.

Author information

  • 1Brigham & Women's Hospital, 65 Landsdowne Street, Fourth Floor, Cambridge, MA 02139, USA.

Abstract

Since leucine-rich repeat kinase 2 (LRRK2) was linked to Parkinson's disease in 2004, kinase activity of LRRK2 has been believed to play a critical role in the pathogenesis of Parkinson's disease. As a result, identification of LRRK2 inhibitors has been a focus for drug discovery. However, most LRRK2 mutations do not simply increase kinase activity. In this review we summarize the potential mechanisms that regulate the kinase activity of LRRK2. We outline some currently available kinase inhibitors, including the identification of a DFG-out (type-II) inhibitor. Finally, we discuss the relationship of LRRK2 with tau and α-synuclein. The fact that all three proteins are autophapgy-related provides a future strategy for the identification of LRRK2 physiological substrate(s).

PMID:
22924508
[PubMed - indexed for MEDLINE]
PMCID:
PMC3569718
Free PMC Article
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Atypon Icon for PubMed Central
    Loading ...
    Write to the Help Desk